19 February 2016 - AstraZeneca today announced that the European Commission has granted marketing authorisation for Brilique (ticagrelor) at a new 60 mg dose for the treatment of patients who have suffered a heart attack at least one year prior and are at high risk of developing a further atherothrombotic event. Treatment may be started as continuation therapy after an initial one-year treatment with Brilique 90mg and aspirin or other dual anti platelet therapy.

For more details, go to: https://www.astrazeneca.com/our-company/media-centre/press-releases/2016/Brilique-ticagrelor-approved-in-EU-for-extended-treatment-of-patients-with-history-of-heart-attack-19022016.html